[A case of CA19-9 producing transitional cell carcinoma of the ureter effectively responsive to combination chemotherapy].
We report a case of CA19-9 producing transitional cell carcinoma of the right ureter effectively responsive to combination chemotherapy (methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) regimen) in a 53-year-old woman. The maximum level of serum CA19-9 showed 3,000 U/ml and clinical staging of the tumor was T4 N3 M0. Marked regression of the tumor was identified by computed tomographic scan and the level of serum CA19-9 returned to the normal range after 3 courses of M-VAC therapy. Right total nephro-ureterectomy and partial cystectomy was done and the surgical specimen revealed no viable tumors. She is alive without evidence of local recurrence or metastasis at 6 months after resection. The serum CA19-9 level was useful for monitoring the clinical course.
Kanai
S
S
Department of Urology, Kakegawa General Hospital.
Takagi
Y
Y
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000096:biosynthesis* / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D014057:Tomography, X-Ray Computed; D014513:Ureter / Q000601:surgery; D014516:Ureteral Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate